Page 26 - FLIPBOOK
P. 26
Summary
• Prostate radiotherapy did not improve survival for unselected patients
(HR=0·92, 95%CI 0·80-1·06; p=0.266)
• Prostate radiotherapy did improve survival (from 73% to 81% at 3 years) in
those with a low metastatic burden (HR=0·68, 95%CI 0·52-0·90; p=0·007).
Test for interaction: p=0.0098
• Mirrors benefit seen in HORRAD trial
• Implies potential benefit in cN+M0 disease taken with known survival gain
with radiotherapy in N0M0 disease
Burdett S, Boeve LM, Ingleby FC, et al: Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol,
2019
Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3
trial. Lancet 392:2353-2366, 2018 MRC CTU at UCL
